Athersys (ATHX +6.4%) gets a boost today, possibly from an upbeat Seeking Alpha piece that touts its strong pipeline. ATHX is a clinical stage biopharmaceutical company with a number of potential catalysts in its portfolio. Its most advanced programs are in the area of regenerative medicine using its stem cell therapy called MultiStem for the treatment of ischemic stroke. StemCells (STEM -2.3%) slips, possibly on the same article, which says it's in pre-clinical trials for the same indication, but its product isn't as advanced as that of ATHX.
Athersys (ATHX +6.4%) gets a boost today, possibly from an upbeat Seeking Alpha piece that touts...
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs